ArticleHIV medicine2025
Survival among medically insured and treated head and neck cancer patients with and without HIV in South Africa.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo assess the association of HIV and overall survival among medically insured head and neck cancer (HNC) patients in South Africa and to examine factors associated with the type of treatment received.
methodsWe used reimbursement claims data from a South African medical insurance scheme database from 1 January 2011 to 1 July 2020. We included individuals with at least two International Classification of Diseases (ICD-10) codes for HNC and at least one cancer treatment code within 180 days of the HNC diagnosis. We used logistic regression to identify factors associated with receiving a specific type of cancer treatment and Cox proportional hazards models to examine factors associated with all-cause mortality.
resultsWe included 566 HNC patients, 49 of whom lived with HIV and 383 were male. Patients with HIV were substantially younger at HNC diagnosis (median age: 52.5 years) than patients without HIV (median age: 61.6 years). We found no clear association between HIV status and the treatment type received. The median survival was 3.78 years (95% confidence interval [CI] 3.01-6.08) and the five-year survival was 46.0% (95% CI 41.2%-51.5%). The risk of death was higher among patients with HIV than those without HIV (adjusted hazard ratio 1.68; 95% CI 1.00-2.81).
conclusionMedically insured HNC patients in South Africa with HIV had higher mortality than those without HIV. This underscores the importance of tailored cancer care strategies for HNC patients with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.